Abnormal left ventricular function (HP:0005162)
Inability of the left ventricle to perform its normal physiologic function. Failure is either due to an inability to contract the left ventricle or the inability to relax completely and fill with blood during diastole.
Synonyms:Impaired left ventricular function, Left ventricular dysfunction, Left ventricular failure, Left ventricular impairment, Left-sided heart failure
Pubmed References:PMID:10956313
Cross References:MSH:D006333, SNOMEDCT_US:275514001, SNOMEDCT_US:85232009, UMLS:C0023212, UMLS:C0553982
KEGG pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Adrenergic signaling in cardiomyocytes | 6.163e-7 | 0.000009942 | 90.61 | 1295.71 |
| 2 | Cardiac muscle contraction | 0.000009332 | 0.00005271 | 101.56 | 1176.29 |
| 3 | Hypertrophic cardiomyopathy | 0.00001034 | 0.00005271 | 98.04 | 1125.55 |
| 4 | cGMP-PKG signaling pathway | 9.469e-7 | 0.000009942 | 81.09 | 1124.75 |
| 5 | Dilated cardiomyopathy | 0.00001255 | 0.00005271 | 91.69 | 1034.81 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | adult heart development (GO:0007512) | 7.548e-9 | 1.446e-7 | 1427.43 | 26695.75 |
| 2 | positive regulation of cardioblast differentiation (GO:0051891) | 0.000002248 | 0.00002073 | 1665.58 | 21661.60 |
| 3 | regulation of cardioblast differentiation (GO:0051890) | 0.000002248 | 0.00002073 | 1665.58 | 21661.60 |
| 4 | cardiac atrium morphogenesis (GO:0003209) | 1.217e-10 | 6.059e-9 | 887.78 | 20267.77 |
| 5 | cardiac muscle tissue morphogenesis (GO:0055008) | 1.893e-12 | 4.713e-10 | 739.37 | 19957.87 |
GO: Molecular function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | voltage-gated sodium channel activity involved in cardiac muscle cell action potential (GO:0086006) | 0.002498 | 0.01343 | 555.17 | 3326.77 |
| 2 | nitric-oxide synthase binding (GO:0050998) | 0.003495 | 0.01343 | 370.07 | 2093.27 |
| 3 | co-SMAD binding (GO:0070410) | 0.004990 | 0.01343 | 246.68 | 1307.49 |
| 4 | calcium channel inhibitor activity (GO:0019855) | 0.005488 | 0.01372 | 222.00 | 1155.57 |
| 5 | muscle alpha-actinin binding (GO:0051371) | 0.007476 | 0.01744 | 158.54 | 776.21 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | myofibril (GO:0030016) | 2.616e-7 | 0.000006279 | 356.54 | 5403.81 |
| 2 | muscle myosin complex (GO:0005859) | 0.00002354 | 0.0002825 | 384.17 | 4094.01 |
| 3 | cardiac myofibril (GO:0097512) | 0.002498 | 0.01798 | 555.17 | 3326.77 |
| 4 | myosin filament (GO:0032982) | 0.002997 | 0.01798 | 444.11 | 2580.41 |
| 5 | voltage-gated sodium channel complex (GO:0001518) | 0.008469 | 0.03785 | 138.71 | 661.82 |
Hub genes as predicted biomarker & predicted FDA approved drugs
| Hub Genes (ranked) | FDA approved drugs |
| MYH6 | – |
| TNNI3 | – |
| NKX2-5 | – |
| GATA4 | WARFARIN |
| SCN5A | INDECAINIDE, BENZONATATE, FOSPHENYTOIN, MORICIZINE, HEXYLCAINE, PROCAINAMIDE, MEXILETINE, DISOPYRAMIDE |
| NPPA | CLORTHALIDONE, AMLODIPINE |
| MYH7 | – |
| TBX20 | – |
| ACTA2 | – |
| LDB3 | – |
